comprehensive -WSS

comprehensive

author：knowledge 2025-09-28 06:26:03 - browse：6817

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Shionogi licenses Pompe disease therapy from Maze Therapeutics

leisure time

WSS

First Opinion Podcast: Long Covid needs a new approach

2023 STAT Wunderkinds: get to know the winners

UnitedHealth’s board chair also owns a personal investment firm

Solve the antibiotic resistance crisis with preventive drugs

FDA struggles to regulate food additives, sometimes for decades

UnitedHealth’s board chair also owns a personal investment firm

knowledge

comprehensive

leisure time

Moonlake's readout produced a cash windfall. Risks remain

Study: AI not yet building 'n

Anesthesiologist group: stop taking Ozempic before surgery

Sanofi strikes deal with Novavax, boosting the vaccine maker

Affirmative action in medical school literally saved lives

Steward Health Care files for bankruptcy

Alkermes shareholders re

STAT Summit: Biotech founders on deal

Trump demands the U.S. pay no more for drugs than other countries … again

Beam Therapeutics to lay off 20% of its staff, re

focus

After gene therapy, two congenitally deaf children hear for the first time

UnitedHealth’s board chair also owns a personal investment firm

Senate committee scrutinizes Medicare Advantage brokers

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Lawmakers consider Medicare pay reforms for doctors

FDA warns J&J's Abiomed: We will regulate your software

Wikipedia

hotspot

explore

hotspot